You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加科思-B(01167.HK)公佈中期業績 研發開支增加45.1%至1.77億元 將擴大在中國的製造能力
格隆匯 08-23 20:27

格隆匯8月23日丨加科思-B(01167.HK)公佈,截至2022年6月30日止六個月,公司取得了人民幣5470萬元的收入,這歸因於與AbbVie簽訂以研發、製造及商業化SHP2抑制劑的許可及合作協議所產生的研發成本報銷。期內虧損由截至2021年6月30日止六個月的人民幣1.37億元減至期間人民幣1.28億元。

公司的研發開支由截至2021年6月30日止六個月的人民幣1.22億元增加人民幣5490萬元或45.1%至截至2022年6月30日止六個月的人民幣1.77億元,主要是由於公司臨牀候選藥物的進展、臨牀前研究組合的拓展及隨相關研發部門擴張而增加的員工成本。

公司於2022年上半年在資產的臨牀發展方面取得莫大進展。於上半年,公司已展開合共七項新研究,並就該等試驗達成首名患者入組。另外,KRASG12C抑制劑JAB-21822單藥治療試驗的I/IIa期劑量遞增及擴展試驗已在中國完成。2022年美國臨牀腫瘤醫學會週年大會報吿的初步數據顯示,JAB-21822的療效令人滿意,安全性可予接受。JAB-21822單藥治療的關鍵試驗將於2022年下半年在中國進行。

公司是篩選、發現及開發全球腫瘤治療創新機制潛在首創療法方面的領跑者。通過繼續加強公司的藥物發現平台並推進公司的管線,公司有望通過一系列轉化療法獲得全球市場領導地位,並有望使癌症患者受益匪淺。此外,公司亦計劃在實現臨牀進展並期望獲得監管批准時,為公司的綜合發現及開發平台增加世界一流的製造及商業化能力。

在短期內,公司計劃着重於尋求以下重大機遇:在中國及全球開發SHP2資產;開發、商業化及擴大KRAS組合;開發P53組合;以獨特載荷推進iADC項目;不斷推進及拓展靶向其他多種有希望的信號通路的其他管線;通過合作把握全球市場機會並擴展到令人矚目的研究領域;擴充公司的人才庫並提升跨區域業務能力;升級公司的先進研發平台;擴大公司在中國的製造能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account